Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PL-MLP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
PL-MLP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
PL-MLP: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
NDV-3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
NDV-3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
NDV-3: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
CAN-1012 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
CAN-1012 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
CAN-1012: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
PBT-434 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
PBT-434 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
PBT-434: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
BI-1815368 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
BI-1815368 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
BI-1815368: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Tobramycin sulfate /Vancomycin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Tobramycin sulfate /Vancomycin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Tobramycin sulfate /Vancomycin Hydrochloride: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
LYCovMab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
LYCovMab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
LYCovMab: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Thiostrepton Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Thiostrepton Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Thiostrepton: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Blixeprodil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Blixeprodil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Blixeprodil: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
[18F]-AzaFol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
[18F]-AzaFol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
[18F]-AzaFol: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Elifactant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Elifactant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Elifactant: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Enistimagene Setitucel/Damistimagene Matitucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Enistimagene Setitucel/Damistimagene Matitucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Enistimagene Setitucel/Damistimagene Matitucel: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →